These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 498169)

  • 41. Is more better?
    Cooper MR
    Cancer Invest; 1992; 10(1):93-4. PubMed ID: 1735015
    [No Abstract]   [Full Text] [Related]  

  • 42. Melphalan and myeloma. Experience with a low-dose continuous regimen.
    McArthur JR; Athens JW; Wintrobe MM; Cartwright GE
    Ann Intern Med; 1970 May; 72(5):665-70. PubMed ID: 5448096
    [No Abstract]   [Full Text] [Related]  

  • 43. [Myeloma, melphalan and acute myelo-monocytic leukemia. Apropos of a case].
    Cywiner-Golenzer C; Adotti F; Marsan C; Quillard A; Henon P; Grimaldi A; Dryll A
    Sem Hop; 1974 Jan; 50(3):207-11. PubMed ID: 4367926
    [No Abstract]   [Full Text] [Related]  

  • 44. [On clinical use of high single doses of sarcolysine and exdoxan (cyclophosphan)].
    Garin AM; Astrakhan VI; Bychkov MB; Larionov LF; Perevodchikova NI
    Vopr Onkol; 1965; 11(10):3-9. PubMed ID: 5333877
    [No Abstract]   [Full Text] [Related]  

  • 45. [Results of combined treatment of advanced forms of multiple myeloma with vincristine, melphalan, cyclophosphamide and prednisone (VMCP) and with vincristine, doxorubicin, cyclophosphamide and prednisone (VDCP)].
    Robak T; Krykowski E; Płuzańska A; Olszańska-Skorek T; Urbańska-Ryś H; Polkowska-Kulesza E; Błasińska-Morawiec M; Mazurowa A
    Pol Tyg Lek; 1983 Apr; 38(16):481-4. PubMed ID: 6579509
    [No Abstract]   [Full Text] [Related]  

  • 46. Cyclophosphamide vs melphalan in treatment of plasma cell myeloma.
    Rivers SL; Patno ME
    JAMA; 1969 Feb; 207(7):1328-34. PubMed ID: 4179565
    [No Abstract]   [Full Text] [Related]  

  • 47. Intermediate dose of intravenous melphalan in advanced multiple myeloma.
    Tsakanikas S; Papanastasiou K; Stamatelou M; Maniatis A
    Oncology; 1991; 48(5):369-71. PubMed ID: 1745483
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bortezomib plus melphalan and prednisone for multiple myeloma.
    Tsubokura M; Kami M; Komatsu T
    N Engl J Med; 2008 Dec; 359(24):2613; author reply 2613-4. PubMed ID: 19090031
    [No Abstract]   [Full Text] [Related]  

  • 49. Multiple myeloma. II. The value of melphalan.
    Bernard DB; Lynch SR; Bothwell TH; Bezwoda WR; Stevens K; Shulman G
    S Afr Med J; 1974 May; 48(24):1026-8. PubMed ID: 4835772
    [No Abstract]   [Full Text] [Related]  

  • 50. Ondansetron--a new safe and effective antiemetic in patients receiving high-dose melphalan.
    Viner CV; Selby PJ; Zulian GB; Gore ME; Butcher ME; Wootton CM; McElwain TJ
    Cancer Chemother Pharmacol; 1990; 25(6):449-53. PubMed ID: 2138064
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oral melphalan pharmacokinetics: influence of interferon-induced fever.
    Ehrsson H; Eksborg S; Wallin I; Osterborg A; Mellstedt H
    Clin Pharmacol Ther; 1990 Jan; 47(1):86-90. PubMed ID: 2295223
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Therapy of multiple myeloma. Study of hospital patients: 81 cases in 16 years' observation].
    Monti G; Cereda UG; Pessina E; De Micheli N; Grisetti GC; Invernizzi F
    Minerva Med; 1983 Feb; 74(5):155-63. PubMed ID: 6828250
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Schedule dependent cytotoxicity of bortezomib and melphalan in multiple myeloma.
    Popat R; Maharaj L; Oakervee H; Cavenagh J; Joel S
    Br J Haematol; 2013 Jan; 160(1):111-4. PubMed ID: 23078038
    [No Abstract]   [Full Text] [Related]  

  • 54. A case of multiple myeloma terminating with acute myelomonocytic leukemia after long-term melphalan therapy.
    Ota H; Ikeda Y; Shibata T; Hirabayashi N
    Nihon Ketsueki Gakkai Zasshi; 1974 Feb; 37(1):49-57. PubMed ID: 4526861
    [No Abstract]   [Full Text] [Related]  

  • 55. Acute leukemia secondary to multiple myeloma.
    de Gramont A; Rioux E; Shields C
    Can Med Assoc J; 1983 Sep; 129(6):534, 536. PubMed ID: 6576845
    [No Abstract]   [Full Text] [Related]  

  • 56. Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma.
    Borad MJ; Swift R; Berenson JR
    Leukemia; 2005 Jan; 19(1):154-6. PubMed ID: 15496977
    [No Abstract]   [Full Text] [Related]  

  • 57. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.
    Palumbo A; Falco P; Corradini P; Falcone A; Di Raimondo F; Giuliani N; Crippa C; Ciccone G; Omedè P; Ambrosini MT; Gay F; Bringhen S; Musto P; Foà R; Knight R; Zeldis JB; Boccadoro M; Petrucci MT;
    J Clin Oncol; 2007 Oct; 25(28):4459-65. PubMed ID: 17785703
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cyclophosphamide-containing regimen (TCD) is superior to melphalan-containing regimen (MPT) in elderly multiple myeloma patients with renal impairment.
    Song MK; Chung JS; Shin HJ; Moon JH; Lee JJ; Yoon SS; Kim JS; Lee JO; Do YR; Lee HS; Park EK;
    Ann Hematol; 2012 Jun; 91(6):889-96. PubMed ID: 22237937
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of aniline mustard in patients with multiple myeloma.
    Kyle RA; Costa G; Cooper MR; Ogawa M; Silver RT; Glidewell O; Holland JF
    Cancer Res; 1973 May; 33(5):956-60. PubMed ID: 4703127
    [No Abstract]   [Full Text] [Related]  

  • 60. [Erythroleukemia in multiple myeloma. A case report].
    Streuli R; Voellmy W
    Schweiz Med Wochenschr; 1987 Feb; 117(8):286-91. PubMed ID: 3470922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.